These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
644 related articles for article (PubMed ID: 12032333)
1. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333 [TBL] [Abstract][Full Text] [Related]
2. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433 [TBL] [Abstract][Full Text] [Related]
3. Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia with t(7;11)(p15;p15). Yamamoto K; Nakamura Y; Saito K; Furusawa S Br J Haematol; 2000 May; 109(2):423-6. PubMed ID: 10848835 [TBL] [Abstract][Full Text] [Related]
4. [Research advance on molecular genetics of CML blast crisis]. Zhu HQ; Zhang S; Liu XL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935 [TBL] [Abstract][Full Text] [Related]
5. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model. Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801 [TBL] [Abstract][Full Text] [Related]
6. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597 [TBL] [Abstract][Full Text] [Related]
7. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572 [TBL] [Abstract][Full Text] [Related]
8. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063 [TBL] [Abstract][Full Text] [Related]
9. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Neviani P; Santhanam R; Trotta R; Notari M; Blaser BW; Liu S; Mao H; Chang JS; Galietta A; Uttam A; Roy DC; Valtieri M; Bruner-Klisovic R; Caligiuri MA; Bloomfield CD; Marcucci G; Perrotti D Cancer Cell; 2005 Nov; 8(5):355-68. PubMed ID: 16286244 [TBL] [Abstract][Full Text] [Related]
11. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Cuenco GM; Ren R Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838 [TBL] [Abstract][Full Text] [Related]
12. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973 [TBL] [Abstract][Full Text] [Related]
13. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894 [TBL] [Abstract][Full Text] [Related]
14. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380 [TBL] [Abstract][Full Text] [Related]
15. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Wolff NC; Ilaria RL Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355 [TBL] [Abstract][Full Text] [Related]
16. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Kawauchi K; Ogasawara T; Yasuyama M; Ohkawa Si Blood Cells Mol Dis; 2003; 31(1):11-7. PubMed ID: 12850478 [TBL] [Abstract][Full Text] [Related]
17. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]. Buchdunger E Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067 [TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844 [TBL] [Abstract][Full Text] [Related]
20. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]